Stories about survival
- Language:
-
Media:
All
- Period:
- Period:Total
- more
Technische Universität München
Grow faster, die sooner: How growth rates influence the fitness of bacteria
moreEuropean Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
moreDebiopharm successfully completes randomized Phase II study for IAP antagonist Debio 1143 in high risk head & neck cancer patients
moreTechnische Universität München
The physiology of survival: for bacteria, the neighbors co-determine which cell dies first
moreTechnische Universität München
Who will win the Game of Thrones? - Machine learning algorithms predict who will be left standing in "Game of Thrones"
morePivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine
moreMerck and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer
moreBAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study
moreAstellas Pharma Europe Limited
Medivation and Astellas Announce the Phase 3 PREVAIL Trial of XTANDI?(TM) (Enzalutamide) Meets Both Co-Primary Endpoints of Overall Survival and Radiographic Progression-Free Survival in Chemotherapy-Naïve Patients with Advanced Prostate Cancer
more
1